Psilocybin Efficacy With or Without Pimavanserin Pretreatment
NCT07610135
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration. The purpose of this study is to clarify the receptor-level mechanisms underlying psilocybin's effects on mood and well-being, along with the associated neurophysiologic signatures.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Mood (Psychological Function)
- Well Being
- Mood
- Healthy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Johns Hopkins University
- Last updated on ClinicalTrials.gov
- October 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Johns Hopkins Center for Psychedelic and Consciousness Research · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.